The Merkel Cell Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Merkel Cell Carcinoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued products.

GlobalData tracks 69 drugs in development for Merkel Cell Carcinoma by 60 companies/universities/institutes. The top development phase for Merkel Cell Carcinoma is phase ii with 38 drugs in that stage. The Merkel Cell Carcinoma pipeline has 66 drugs in development by companies and three by universities/ institutes. Some of the companies in the Merkel Cell Carcinoma pipeline products market are: Bristol-Myers Squibb, Incyte and F. Hoffmann-La Roche.

The key targets in the Merkel Cell Carcinoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Toll Like Receptor 7 (TLR7).

The key mechanisms of action in the Merkel Cell Carcinoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with eight drugs in Pre-Registration. The Merkel Cell Carcinoma pipeline products include 15 routes of administration with the top ROA being Intravenous and 14 key molecule types in the Merkel Cell Carcinoma pipeline products market including Monoclonal Antibody, and Small Molecule.

Merkel Cell Carcinoma overview

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, ultraviolet exposure, and immune suppression. Symptoms include painless nodules on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatments include chemotherapy, radiation therapy, and surgery.

For a complete picture of Merkel Cell Carcinoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.